Baseline characteristics
| . | n* . | Percentage . |
|---|---|---|
| Patients | 221 | |
| Age, y† | ||
| At diagnosis | 54.2 | (20.7, 96.1) |
| At start of treatment | 55.5 | (20.7, 96.3) |
| Sex | ||
| Male | 170 | (76.9) |
| Female | 51 | (23.1) |
| ECOG at study entry | ||
| 0 | 148 | (67.0) |
| 1 | 58 | (26.2) |
| 2 | 13 | (5.9) |
| Missing | 2 | (0.9) |
| Stage at study entry | ||
| Untreated | 162 | (73.3) |
| Relapsed | 39 | (17.8) |
| Progressive disease | 20 | (9.0) |
| Previous therapies | ||
| Chemotherapy | 9 | (4.1) |
| Interferon | 51 | (23.1) |
| Radiotherapy | 1 | (0.5) |
| Splenectomy | 22 | (10.0) |
| Others | 5 | (2.3) |
| Organ involvement | ||
| Hepatomegaly | 28 | (12.7) |
| Lymphadenopathy | 31 | (14.0) |
| Splenomegaly | 147 | (66.5) |
| Blood values† | ||
| Hemoglobin, g/dL | 11.4 | (4.5, 16.3) |
| Platelets, ×109/L | 78 | (4.3, 318.0) |
| Leukocytes, ×109/L | 2.7 | (0.2-41.1) |
| Monocytes, ×109/L | 0.1 | (0.0, 12.4) |
| LDH, U/L | 323.5 | (81.0, 792.0) |
| . | n* . | Percentage . |
|---|---|---|
| Patients | 221 | |
| Age, y† | ||
| At diagnosis | 54.2 | (20.7, 96.1) |
| At start of treatment | 55.5 | (20.7, 96.3) |
| Sex | ||
| Male | 170 | (76.9) |
| Female | 51 | (23.1) |
| ECOG at study entry | ||
| 0 | 148 | (67.0) |
| 1 | 58 | (26.2) |
| 2 | 13 | (5.9) |
| Missing | 2 | (0.9) |
| Stage at study entry | ||
| Untreated | 162 | (73.3) |
| Relapsed | 39 | (17.8) |
| Progressive disease | 20 | (9.0) |
| Previous therapies | ||
| Chemotherapy | 9 | (4.1) |
| Interferon | 51 | (23.1) |
| Radiotherapy | 1 | (0.5) |
| Splenectomy | 22 | (10.0) |
| Others | 5 | (2.3) |
| Organ involvement | ||
| Hepatomegaly | 28 | (12.7) |
| Lymphadenopathy | 31 | (14.0) |
| Splenomegaly | 147 | (66.5) |
| Blood values† | ||
| Hemoglobin, g/dL | 11.4 | (4.5, 16.3) |
| Platelets, ×109/L | 78 | (4.3, 318.0) |
| Leukocytes, ×109/L | 2.7 | (0.2-41.1) |
| Monocytes, ×109/L | 0.1 | (0.0, 12.4) |
| LDH, U/L | 323.5 | (81.0, 792.0) |